


AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions, and listing of claims in the application.

1 (Currently Amended).

A compound of the structural formula I:



Formula I

or a pharmaceutically acceptable salt, enantiomer, diastereomer or mixture thereof:
wherein,

M, M1, and M2, independently are CH or N;

W represents $X-\overset{\text{O}}{\parallel}{C}-Q\begin{matrix} R_2 \\ R_3 \end{matrix}$ or $(CH_2)_nR_9$;

R represents hydrogen, or C₁₋₆ alkyl;

X represents $-(CHR_7)_p-$, or a bond;

Y represents $-(CH_2)_r-$, $-\text{CO}(CH_2)_n-$, $-\text{SO}_2-$, $-\text{O}-$, $-\text{S}-$, $-\text{CH}(\text{OR}')-$, or CONR' ;

R' represents hydrogen, C₁₋₁₀ alkyl, $-(CH_2)_nC_{1-6}$ alkoxy, $-(CH_2)_nC_{3-8}$ cycloalkyl, $-(CH_2)_nC_{3-10}$ heterocyclyl, said alkyl, heterocyclyl, aryl or heteroaryl optionally substituted with 1-3 groups selected from R^a;

or, R' and R₆ taken together with the intervening N atom of CONR' of Y to form a 4-10 membered carbocyclic or heterocyclic ring optionally interrupted by 1-3 atoms of O, S, C(O) or NR, and optionally having 1-4 double bonds, and optionally substituted by 1-3 groups selected from R^a;

Q represents N, CR_Y, or O, wherein R₂ is absent when Q is O;

R_Y represents H, C₁₋₁₀ alkyl, C₁₋₆ alkylSR, -(CH₂)_nO(CH₂)_mOR, -(CH₂)_nC₁₋₆ alkoxy, -(CH₂)_nC₃₋₈ cycloalkyl, -(CH₂)_nC₃₋₁₀ heterocyclyl, -(CH₂)_nC₅₋₁₀ heteroaryl, -N(R)₂, -COOR, or -(CH₂)_nC₆₋₁₀ aryl, said alkyl, heterocyclyl, aryl or heteroaryl optionally substituted with 1-5 groups selected from R^a;

or, R₂-Q-R₃ form a 3-15 membered carbocyclic or heterocyclic ring or fused ring, optionally interrupted by 1-3 atoms of O, S, C(O) or NR, and optionally having 1-5 double bonds, and optionally substituted by 1-3 groups selected from R^a;

R_w represents H, C₁₋₆ alkyl, -C(O)C₁₋₆ alkyl, -C(O)OC₁₋₆ alkyl, -SO₂N(R)₂, -SO₂C₁₋₆ alkyl, -SO₂C₆₋₁₀ aryl, NO₂, CN or -C(O)N(R)₂;

R₂ represents hydrogen, C₁₋₁₀ alkyl, C₁₋₆ alkylSR, -(CH₂)_nO(CH₂)_mOR, -(CH₂)_nC₁₋₆ alkoxy, -(CH₂)_nC₃₋₈ cycloalkyl, -(CH₂)_nC₃₋₁₀ heterocyclyl, -(CH₂)_nC₅₋₁₀ heteroaryl, -N(R)₂, -COOR, or -(CH₂)_nC₆₋₁₀ aryl, said alkyl, heterocyclyl, aryl or heteroaryl optionally substituted with 1-3 groups selected from R^a;

R₃ represents hydrogen, C₁₋₁₀ alkyl, -(CH₂)_nC₃₋₈ cycloalkyl, -(CH₂)_nC₃₋₁₀ heterocyclyl, -(CH₂)_nC₅₋₁₀ heteroaryl, -(CH₂)_nCOOR, -(CH₂)_nC₆₋₁₀ aryl, -(CH₂)_nNHR₈, -(CH₂)_nN(R)₂, -(CH₂)_nNHCOOR, -(CH₂)_nN(R₈)CO₂R, -(CH₂)_nN(R₈)COR, -(CH₂)_nNHCOR, -(CH₂)_nCONH(R₈), aryl, -(CH₂)_nC₁₋₆ alkoxy, CF₃, -(CH₂)_nSO₂R, -(CH₂)_nSO₂N(R)₂, -(CH₂)_nCON(R)₂, -(CH₂)_nCONHC(R)₃, -(CH₂)_nCOR₈, nitro, cyano or halogen, said alkyl, alkoxy, heterocyclyl, aryl or heteroaryl optionally substituted with 1-3 groups of R^a;

R₄ and R₅ independently represent hydrogen, C₁₋₆ alkoxy, OH, ~~OCOR₃~~, C₁₋₆ alkyl, ~~COOR~~, SO₃H, ~~O(CH₂)_nN(R)₂~~, ~~O(CH₂)_nCO₂R~~, C₁₋₆ alkylcarbonyl, S(O)_qR_Y, (CH₂)_nOPO(OH)₂, O(CH₂)_nOPO(OH)₂, ~~N(R)₂~~, CF₃, nitro, cyano or halogen where said alkyl, and alkoxy, are optionally substituted with 1-7 groups of R^a;

R₆ represents hydrogen, C₁₋₁₀ alkyl, -(CH₂)_nC₆₋₁₀ aryl, -(CH₂)_nC₅₋₁₀ heteroaryl, (C₆₋₁₀ aryl)O-, -(CH₂)_nC₃₋₁₀ heterocyclyl, -(CH₂)_nC₃₋₈ cycloalkyl, -COOR, -C(O)CO₂R, said

aryl, heteroaryl, heterocyclyl and alkyl optionally substituted with 1-3 groups selected from R^a ;

R_7 represents hydrogen, C_{1-6} alkyl, $-(CH_2)_nCOOR$ or $-(CH_2)_nN(R)_2$,

R_8 represents $-(CH_2)_nC_{3-8}$ cycloalkyl, $-(CH_2)_n$ 3-10 heterocyclyl, C_{1-6} alkoxy or $-(CH_2)_nC_{5-10}$ heteroaryl, said heterocyclyl, aryl or heteroaryl optionally substituted with 1-3 groups selected from R^a ;

R_9 represents C_{1-10} alkyl, $-(CH_2)_nC_{1-6}$ alkoxy, $-(CH_2)_nC_{3-8}$ cycloalkyl, $-(CH_2)_nC_{3-10}$ heterocyclyl, $-(CH_2)_nC_{6-10}$ aryl, $-(CH_2)_nC_{5-10}$ heteroaryl, or $-N(R)_2$ wherein said alkyl, alkoxy, cycloalkyl, heterocyclyl, aryl, or heteroaryl are optionally substituted with 1-3 groups selected from R^a ;

R^a represents F, Cl, Br, I, CF_3 , $N(R)_2$, NO_2 , CN, $-COR_8$, $-CONHR_8$, $-CON(R_8)_2$, $-O(CH_2)_nCOOR$, $-NH(CH_2)_nOR$, $-COOR$, $-OCF_3$, $-NHCOR$, $-SO_2R$, $-SO_2NR_2$, $-SR$, $(C_1-C_6$ alkyl)O-, $-(CH_2)_nO(CH_2)_mOR$, $-(CH_2)_nC_{1-6}$ alkoxy, (aryl)O-, $-OH$, $(C_1-C_6$ alkyl) $S(O)_m$ -, $H_2N-C(=NH)-$, $(C_1-C_6$ alkyl) $C(O)-$, $(C_1-C_6$ alkyl) $OC(O)NH-$, $-(C_1-C_6$ alkyl) $NR_w(CH_2)_nC_{3-10}$ heterocyclyl- R_w , $-(C_1-C_6$ alkyl) $O(CH_2)_nC_{3-10}$ heterocyclyl- R_w , $-(C_1-C_6$ alkyl) $S(CH_2)_nC_{3-10}$ heterocyclyl- R_w , $-(C_1-C_6$ alkyl)- C_{3-10} heterocyclyl- R_w , $-(CH_2)_n-Z^1-C(=Z^2)N(R)_2$, $-(C_{2-6}$ alkenyl) $NR_w(CH_2)_nC_{3-10}$ heterocyclyl- R_w , $-(C_{2-6}$ alkenyl) $O(CH_2)_nC_{3-10}$ heterocyclyl- R_w , $-(C_{2-6}$ alkenyl) $S(CH_2)_nC_{3-10}$ heterocyclyl- R_w , $-(C_{2-6}$ alkenyl)- C_{3-10} heterocyclyl- R_w , $-(C_{2-6}$ alkenyl)- $Z^1-C(=Z^2)N(R)_2$, $-(CH_2)_nSO_2R$, $-(CH_2)_nSO_3H$, $-(CH_2)_nPO(OR)_2$, $-(CH_2)_nOPO(OR)_2$, $-O(CH_2)_nSO_2R$, $-O(CH_2)_nPO(OR)_2$, $-O(CH_2)_nOPO(OR)_2$, cyclohexyl, morpholinyl, piperidyl, pyrrolidinyl, thiophenyl, phenyl, pyridyl, imidazolyl, oxazolyl, isoxazolyl, thiazolyl, thienyl, furyl, isothiazolyl, C_{2-6} alkenyl, and C_1-C_{10} alkyl, said alkyl, alkenyl, alkoxy, phenyl, pyridyl, imidazolyl, oxazolyl, isoxazolyl, thiazolyl, thienyl, furyl, and isothiazolyl optionally substituted with 1-3 groups selected from C_1-C_6 alkyl, COOR, SO_3H , OH, F, Cl, Br, I, and $-O(CH_2)_nCH(OH)CH_2SO_3H$;

Z^1 and Z^2 independently represents NR_w , O, CH_2 , or S;

m is 0-3;

n is 0-3;

q is 0-2;


r is 0-6 and

p is 0-2,

provided that when R₄ and R₅ are hydrogen and YR₆ is ethyl then W is not tropine and when R₄ and R₅ are hydrogen and YR₆ is phenyl then W is not C₁₋₄ alkyl.

2. Cancel.

3(Original). A compound according to claim 2 wherein W represents



4(Original). A compound according to claim 2 wherein W represents (CH₂)_nR₉.

5(Original). A compound according to claim 3 wherein Y is -CO(CH₂)_n, - (CH₂)_r-or CH(OR) and Q is N or R_y.

6(Original). A compound according to claim 5 wherein R₆ is C₁₋₁₀ alkyl, (CH₂)_nC₆₋₁₀ aryl, (CH₂)_nC₅₋₁₀ heteroaryl, (CH₂)_nC₃₋₁₀ heterocyclyl, or (CH₂)_nC₃₋₈ cycloalkyl, said aryl, heteroaryl, heterocyclyl and alkyl optionally substituted with 1 to 3 groups of R^a, Y is -CO(CH₂)_n, Q is N, and R₂ and R₃ are independently selected from C₁₋₁₀ alkyl, (CH₂)_nC₃₋₈ cycloalkyl, -(CH₂)_n-5~10-membered heteroaryl, -(CH₂)_nC₆₋₁₀ aryl, -(CH₂)_n-3~10-membered heterocyclyl, and C₁₋₆ alkylOH said cycloalkyl, aryl, heteroaryl, heterocyclyl and alkyl optionally substituted with 1 to 3 groups of R^a.

7(Currently Amended). A compound which is:
1-(1-Benzyl-6-methoxy-1*H*-benzimidazol-2-yl)-2,2-dimethylpropan-1-one,
1-(1-benzyl-5-methoxy-1*H*-benzimidazol-2-yl)-2,2-dimethylpropan-1-one,
1-(5-Methoxy-1*H*-benzimidazol-2-yl)-2,2-dimethylpropan-1-one,
Methyl [2-(2,2-dimethylpropanoyl)-6-methoxy-1*H*-benzimidazol-1-yl]acetate,
Methyl [2-(2,2-dimethylpropanoyl)-5-methoxy-1*H*-benzimidazol-1-yl]acetate,
[2-(2,2-Dimethylpropanoyl)-5-methoxy-1*H*-benzimidazol-1-yl]acetic acid,
2-[2-(2,2-Dimethylpropanoyl)-5-methoxy-1*H*-benzimidazol-1-yl]-*N,N*-bis(3-methylbutyl)acetamide,

1-(Diethoxymethyl)-6-methoxy-1*H*-benzimidazole,
1-(diethoxymethyl)-5-methoxy-1*H*-benzimidazole,
1-(6-Methoxy-1*H*-benzimidazol-2-yl)-2,2-dimethylpropan-1-one,
N,N-Dibutyl-2-[2-(2,2-dimethylpropanoyl)-5-methoxy-1*H*-benzimidazol-1-yl]acetamide,
2-[2-(2,2-Dimethylpropanoyl)-5-methoxy-1*H*-benzimidazol-1-yl]-*N,N*-diisobutylacetamide,
2-[2-(2,2-Dimethylpropanoyl)-5-methoxy-1*H*-benzimidazol-1-yl]-*N,N*-dipropylacetamide,
N-(Cyclopropylmethyl)-2-[2-(2,2-dimethylpropanoyl)-5-methoxy-1*H*-benzimidazol-1-yl]-*N*-
propylacetamide,
2-[2-(2,2-Dimethylpropanoyl)-5-methoxy-1*H*-benzimidazol-1-yl]-*N*-ethyl-*N*-(3-
methylbutyl)acetamide,
N-Butyl-2-[2-(2,2-dimethylpropanoyl)-5-methoxy-1*H*-benzimidazol-1-yl]-*N*-ethylacetamide,
N-Cyclohexyl-2-[2-(2,2-dimethylpropanoyl)-5-methoxy-1*H*-benzimidazol-1-yl]-*N*-
ethylacetamide,
2-[2-(2,2-Dimethylpropanoyl)-5-methoxy-1*H*-benzimidazol-1-yl]-*N*-ethyl-*N*-1,3-thiazol-2-
ylacetamide,
[2-(2,2-Dimethylpropanoyl)-6-methoxy-1*H*-benzimidazol-1-yl]acetic acid,
2-[2-(2,2-Dimethylpropanoyl)-6-methoxy-1*H*-benzimidazol-1-yl]-*N,N*-bis(3-
methylbutyl)acetamide,
N,N-Dibutyl-2-[2-(2,2-dimethylpropanoyl)-6-methoxy-1*H*-benzimidazol-1-yl]acetamide,
2-[2-(2,2-Dimethylpropanoyl)-6-methoxy-1*H*-benzimidazol-1-yl]-*N,N*-diisobutylacetamide,
2-[2-(2,2-Dimethylpropanoyl)-6-methoxy-1*H*-benzimidazol-1-yl]-*N,N*-dipropylacetamide,
N-(Cyclopropylmethyl)-2-[2-(2,2-dimethylpropanoyl)-6-methoxy-1*H*-benzimidazol-1-yl]-*N*-
propylacetamide,
2-[2-(2,2-Dimethylpropanoyl)-6-methoxy-1*H*-benzimidazol-1-yl]-*N*-ethyl-*N*-(3-
methylbutyl)acetamide,
N-Butyl-2-[2-(2,2-dimethylpropanoyl)-6-methoxy-1*H*-benzimidazol-1-yl]-*N*-ethylacetamide,
N-Cyclohexyl-2-[2-(2,2-dimethylpropanoyl)-6-methoxy-1*H*-benzimidazol-1-yl]-*N*-
ethylacetamide,
2-[2-(2,2-Dimethylpropanoyl)-6-methoxy-1*H*-benzimidazol-1-yl]-*N*-ethyl-*N*-1,3-thiazol-2-
ylacetamide,
N-(3,3-Dimethylbutyl)-2-[2-(2,2-dimethylpropanoyl)-6-methoxy-1*H*-benzimidazol-1-yl]-*N*-
ethylacetamide,

1-[2-(2,2-Dimethylpropanoyl)-5-methoxy-1*H*-benzimidazol-1-yl]-3,3-dimethylbutan-2-one,
1-[2-(2,2-Dimethylpropanoyl)-6-methoxy-1*H*-benzimidazol-1-yl]-3,3-dimethylbutan-2-one,
1-(1-Benzyl-5-methoxy-1*H*-benzimidazol-2-yl)-2,2-dimethylpropan-1-one,
1-(1-Benzyl-6-methoxy-1*H*-benzimidazol-2-yl)-2,2-dimethylpropan-1-one,
1-[1-(3,3-Dimethylbutyl)-5-methoxy-1*H*-benzimidazol-2-yl]-2,2-dimethylpropan-1-one,
1-[1-(3,3-Dimethylbutyl)-6-methoxy-1*H*-benzimidazol-2-yl]-2,2-dimethylpropan-1-one,
N,N-Dibutyl-2-[2-(2,2-dimethylpropyl)-5-methoxy-1*H*-benzimidazol-1-yl]acetamide,
N,N-Dibutyl-2-[2-(2,2-dimethylpropyl)-6-methoxy-1*H*-benzimidazol-1-yl]acetamide,
1-[2-(2,2-Dimethylpropyl)-5-methoxy-1*H*-benzimidazol-1-yl]-3,3-dimethylbutan-2-one,
1-[2-(2,2-Dimethylpropyl)-6-methoxy-1*H*-benzimidazol-1-yl]-3,3-dimethylbutan-2-one,
1-[5-Methoxy-2-(2-phenylethyl)-1*H*-benzimidazol-1-yl]-3,3-dimethylbutan-2-one,
1-[6-Methoxy-2-(2-phenylethyl)-1*H*-benzimidazol-1-yl]-3,3-dimethylbutan-2-one,
1-(5-Methoxy-2-phenyl-1*H*-benzimidazol-1-yl)-3,3-dimethylbutan-2-one,
1-(6-Methoxy-2-phenyl-1*H*-benzimidazol-1-yl)-3,3-dimethylbutan-2-one,
1-(2-Benzyl-5-methoxy-1*H*-benzimidazol-1-yl)-3,3-dimethylbutan-2-one,
1-(2-Benzyl-6-methoxy-1*H*-benzimidazol-1-yl)-3,3-dimethylbutan-2-one,
~~*N,N* dibutyl 2-(2 isobutyryl 6 methoxy 1*H* imidazo[4,5-*c*]pyridin-1-yl)acetamide,~~
~~*N,N* dibutyl 2-(2 isobutyryl 5 methoxy 3*H* imidazo[4,5-*b*]pyridin-3-yl)acetamide,~~
~~*N,N* dibutyl 2-(2 isobutyryl 6 methoxy 1*H* imidazo[4,5-*b*]pyridin-1-yl)acetamide,~~
~~*N,N* dibutyl 2-(8 isobutyryl 2 methoxy 9*H* purin-9-yl)acetamide,~~
~~*N,N* dibutyl 2-(2 isobutyryl 6 methoxy 1*H* imidazo[4,5-*b*]pyrazin-1-yl)acetamide,~~
~~*N,N* dibutyl 2-(6 isobutyryl 3 methoxy 5*H* imidazo[4,5-*c*]pyridazin-5-yl)acetamide,~~
~~*N,N* dibutyl 2-(6 isobutyryl 3 methoxy 5*H* imidazo[4,5-*c*][1,2,4]triazin-5-yl)acetamide,~~
~~*N,N* dibutyl 2-[2-(2,2 dimethylpropanoyl)-5-methoxy-3*H* imidazo[4,5-*b*]pyridin-3-yl]acetamide~~
~~*N,N* dibutyl 2-(2 (2,2 dimethylpropanoyl)-6-methoxy-1*H* imidazo[4,5-*c*]pyridin-1-yl)acetamide,~~
~~*N,N* dibutyl 2-(2 (2,2 dimethylpropanoyl)-6-methoxy-1*H* imidazo[4,5-*b*]pyridin-1-yl)acetamide,~~
~~*N,N* dibutyl 2-(8 (2,2 dimethylpropanoyl)-2-methoxy-9*H* purin-9-yl)acetamide,~~
~~*N,N* dibutyl 2-(2 (2,2 dimethylpropanoyl)-6-methoxy-1*H* imidazo[4,5-*b*]pyrazin-1-yl)acetamide,~~
~~*N,N* dibutyl 2-(6 (2,2 dimethylpropanoyl)-3-methoxy-5*H* imidazo[4,5-*c*]pyridazin-5-yl)acetamide,~~
~~*N,N* dibutyl 2-(6 (2,2 dimethylpropanoyl)-3-methoxy-5*H* imidazo[4,5-*c*][1,2,4]triazin-5-yl)acetamide,~~
2-[2-(2,2 dimethylpropanoyl)-5-methoxy-3*H* imidazo[4,5-*b*]pyridin-3-yl]-*N,N*-bis(3-methylbutyl)acetamide,
2-(2-(2,2 dimethylpropanoyl)-6-methoxy-1*H* imidazo[4,5-*c*]pyridin-1-yl)-*N,N*-bis(3-methylbutyl)acetamide,
2-(2-(2,2 dimethylpropanoyl)-6-methoxy-1*H* imidazo[4,5-*b*]pyridin-1-yl)-*N,N*-bis(3-methylbutyl)acetamide,
2-(8-(2,2 dimethylpropanoyl)-2-methoxy-9*H* purin-9-yl)-*N,N*-bis(3-methylbutyl)acetamide,

~~2-(2-(2,2-dimethylpropanoyl)-6-methoxy-1*H*-imidazo[4,5-*b*]pyrazin-1-yl)-*N,N*-bis(3-methylbutyl)acetamide,~~
~~2-(6-(2,2-dimethylpropanoyl)-3-methoxy-5*H*-imidazo[4,5-*e*]pyridazin-5-yl)-*N,N*-bis(3-methylbutyl)acetamide,~~
~~2-[6-(2,2-dimethylpropanoyl)-3-methoxy-5*H*-imidazo[4,5-*e*][1,2,4]triazin-5-yl]-*N,N*-bis(3-methylbutyl)acetamide,~~
~~2-(2-isobutyryl-5-methoxy-3*H*-imidazo[4,5-*b*]pyridin-3-yl)-*N,N*-bis(3-methylbutyl)acetamide,~~
~~2-(2-isobutyryl-6-methoxy-1*H*-imidazo[4,5-*e*]pyridin-1-yl)-*N,N*-bis(3-methylbutyl)acetamide,~~
~~2-(2-isobutyryl-6-methoxy-1*H*-imidazo[4,5-*b*]pyridin-1-yl)-*N,N*-bis(3-methylbutyl)acetamide,~~
~~2-(8-isobutyryl-2-methoxy-9*H*-purin-9-yl)-*N,N*-bis(3-methylbutyl)acetamide,~~
~~2-(2-isobutyryl-6-methoxy-1*H*-imidazo[4,5-*b*]pyrazin-1-yl)-*N,N*-bis(3-methylbutyl)acetamide,~~
~~2-(6-isobutyryl-3-methoxy-5*H*-imidazo[4,5-*e*]pyridazin-5-yl)-*N,N*-bis(3-methylbutyl)acetamide,~~
~~2-[6-(2,2-dimethylpropanoyl)-3-methoxy-5*H*-imidazo[4,5-*e*][1,2,4]triazin-5-yl]-*N,N*-bis(3-methylbutyl)acetamide,~~
1-(2-benzoyl-6-methoxy-1*H*-benzimidazol-1-yl)-3,3-dimethylbutan-2-one,
2-(2-benzoyl-6-methoxy-1*H*-benzimidazol-1-yl)-*N,N*-dibutylacetamide,
2-(2-benzoyl-6-methoxy-1*H*-benzimidazol-1-yl)-*N,N*-bis(3-methylbutyl)acetamide,
2-(2-benzoyl-6-methoxy-1*H*-benzimidazol-1-yl)-*N*-butyl-*N*-ethylacetamide,
2-(2-benzoyl-6-methoxy-1*H*-benzimidazol-1-yl)-*N,N*-dipropylacetamide,
2-(2-benzoyl-6-methoxy-1*H*-benzimidazol-1-yl)-*N*-(*tert*-butyl)-*N*-ethylacetamide,
2-(2-benzoyl-6-methoxy-1*H*-benzimidazol-1-yl)-*N*-ethyl-*N*-1,3-thiazol-2-ylacetamide,
[6-methoxy-1-(3-methylbutyl)-1*H*-benzimidazol-2-yl](phenyl)methanone,
[1-(2-ethylbutyl)-6-methoxy-1*H*-benzimidazol-2-yl](phenyl)methanone,
[1-(3,3-dimethylbutyl)-6-methoxy-1*H*-benzimidazol-2-yl](phenyl)methanone,
N-benzyl-2-[2-(2,2-dimethylpropanoyl)-6-methoxy-1*H*-benzimidazol-1-yl]-*N*-ethylacetamide,
2-(2-isobutyryl-6-methoxy-1*H*-benzimidazol-1-yl)-*N,N*-bis(3-methylbutyl)acetamide,
N,N-dibutyl-2-(2-isobutyryl-6-methoxy-1*H*-benzimidazol-1-yl)acetamide,
N,N-diisobutyl-2-(2-isobutyryl-6-methoxy-1*H*-benzimidazol-1-yl)acetamide,
2-(2-isobutyryl-6-methoxy-1*H*-benzimidazol-1-yl)-*N,N*-dipropylacetamide,
N-(cyclopropylmethyl)-2-(2-isobutyryl-6-methoxy-1*H*-benzimidazol-1-yl)-*N*-propylacetamide,
N-ethyl-2-(2-isobutyryl-6-methoxy-1*H*-benzimidazol-1-yl)-*N*-(3-methylbutyl)acetamide,
N-butyl-*N*-ethyl-2-(2-isobutyryl-6-methoxy-1*H*-benzimidazol-1-yl)acetamide,
N-cyclohexyl-*N*-ethyl-2-(2-isobutyryl-6-methoxy-1*H*-benzimidazol-1-yl)acetamide,

N-butyl-2-[2-(2,2-dimethylpropanoyl)-6-methoxy-1*H*-benzimidazol-1-yl]-*N*-propylacetamide,
1-(1-{2-[trans-2,5-dipropylpyrrolidin-1-yl]-2-oxoethyl}-6-methoxy-1*H*-benzimidazol-2-yl)-2,2-dimethylpropan-1-one,
1-(1-{2-[cis-2,5-dipropylpyrrolidin-1-yl]-2-oxoethyl}-6-methoxy-1*H*-benzimidazol-2-yl)-2,2-dimethylpropan-1-one,
1-(2-isobutyryl-6-methoxy-1*H*-benzimidazol-1-yl)-3,3-dimethylbutan-2-one,
N-(3,3-dimethylbutyl)-*N*-ethyl-2-(2-isobutyryl-6-methoxy-1*H*-benzimidazol-1-yl)acetamide,
N-butyl-2-(2-isobutyryl-6-methoxy-1*H*-benzimidazol-1-yl)-*N*-propylacetamide,
N-(3,3-dimethylbutyl)-2-[2-(2,2-dimethylpropanoyl)-6-methoxy-1*H*-benzimidazol-1-yl]-*N*-propylacetamide,
2-[2-(2,2-dimethylpropanoyl)-6-methoxy-1*H*-benzimidazol-1-yl]-*N*-(2,2-dimethylpropyl)-*N*-ethylacetamide,
2-{2-[4-(hydroxymethyl)benzoyl]-6-methoxy-1*H*-benzimidazol-1-yl}-*N,N*-bis(3-methylbutyl)acetamide,
2-{2-[4-(hydroxymethyl)benzoyl]-6-methoxy-1*H*-benzimidazol-1-yl}-*N,N*-diisobutylacetamide,
N-(3,3-dimethylbutyl)-*N*-ethyl-2-{2-[4-(hydroxymethyl)benzoyl]-6-methoxy-1*H*-benzimidazol-1-yl}acetamide,
2-{2-[(4-trans-hydroxycyclohexyl)carbonyl]-6-methoxy-1*H*-benzimidazol-1-yl}-*N,N*-bis(3-methylbutyl)acetamide,
N-(3,3-dimethylbutyl)-2-{2-[(4-trans-hydroxycyclohexyl)carbonyl]-6-methoxy-1*H*-benzimidazol-1-yl}-*N*-propylacetamide,
N-(3,3-dimethylbutyl)-*N*-ethyl-2-{2-[(4-trans-hydroxycyclohexyl)carbonyl]-6-methoxy-1*H*-benzimidazol-1-yl}acetamide,
N,N-bis(3,3-dimethylbutyl)-2-{2-[(4-trans-hydroxycyclohexyl)carbonyl]-6-methoxy-1*H*-benzimidazol-1-yl}acetamide,
2-{2-[(4-cis-hydroxycyclohexyl)carbonyl]-6-methoxy-1*H*-benzimidazol-1-yl}-*N,N*-bis(3-methylbutyl)acetamide,
2-(2-{[4-(hydroxymethyl)-1-methylcyclohexyl]carbonyl}-6-methoxy-1*H*-benzimidazol-1-yl)-*N,N*-bis(3-methylbutyl)acetamide,
N,N-dibutyl-2-(2-{[4-(hydroxymethyl)-1-methylcyclohexyl]carbonyl}-6-methoxy-1*H*-benzimidazol-1-yl)acetamide,
2-(2-{[4-(hydroxymethyl)-1-methylcyclohexyl]carbonyl}-6-methoxy-1*H*-benzimidazol-1-yl)-*N,N*-diisobutylacetamide,

N-(3,3-dimethylbutyl)-*N*-ethyl-2-(2-{[4-(hydroxymethyl)-1-methylcyclohexyl]carbonyl}-6-methoxy-1*H*-benzimidazol-1-yl)acetamide,
N-butyl-2-(2-{[4-(hydroxymethyl)-1-methylcyclohexyl]carbonyl}-6-methoxy-1*H*-benzimidazol-1-yl)-*N*-propylacetamide,
N-(3,3-dimethylbutyl)-2-(2-{[4-(hydroxymethyl)-1-methylcyclohexyl]carbonyl}-6-methoxy-1*H*-benzimidazol-1-yl)-*N*-propylacetamide,
N-ethyl-2-(2-{[4-(hydroxymethyl)-1-methylcyclohexyl]carbonyl}-6-methoxy-1*H*-benzimidazol-1-yl)-*N*-(3-methylbutyl)acetamide,
1-{1-[2-(1-adamantyl)-2-oxoethyl]-6-methoxy-1*H*-benzimidazol-2-yl}-2,2-dimethylpropan-1-one,
1-{1-[2-(1-adamantyl)-2-oxoethyl]-6-methoxy-1*H*-benzimidazol-2-yl}-2-methylpropan-1-one,
1-(2-benzyl-5-methoxy-1*H*-benzimidazol-1-yl)-3,3-dimethylbutan-2-one,
1-(5-methoxy-2-phenyl-1*H*-benzimidazol-1-yl)-3,3-dimethylbutan-2-one,
1-[5-methoxy-2-(2-phenylethyl)-1*H*-benzimidazol-1-yl]-3,3-dimethylbutan-2-one,
or a pharmaceutically acceptable salt, enantiomer, diastereomer or mixture thereof.

8(Original). A method for treating ocular hypertension or glaucoma comprising administration to a patient in need of such treatment a therapeutically effective amount of a compound of structural formula I of claim 1.

9(Original). A method for treating macular edema, macular degeneration, increasing retinal and optic nerve head blood velocity, increasing retinal and optic nerve oxygen tension, and/or a neuroprotective effect comprising administration to a patient in need of such treatment a pharmaceutically effective amount of a compound of claim 1; or a pharmaceutically acceptable salt, enantiomer, diastereomer or mixture thereof.

10. Cancel.

11. Cancel.

12(Original). A composition comprising a compound of formula I of claim 1 and a pharmaceutically acceptable carrier.

13(Original). The composition according to Claim 12 wherein the compound of formula I is applied as a topical formulation, said topical formulation administered as a solution or suspension and optionally containing xanthan gum or gellan gum.

14(Original). A composition according to claim 13 wherein one or more of an active ingredient belonging to the group consisting of: α -adrenergic blocking agent, parasympatho-mimetic agent, sympathomimetic agent, carbonic anhydrase inhibitor, EP4 agonist, a prostaglandin or derivative thereof, hypotensive lipid, neuroprotectant, and/or 5-HT2 receptor agonist is optionally added.

15(Original). A composition according to claim 14 wherein the α -adrenergic blocking agent is timolol, betaxolol, levobetaxolol, carteolol, or levobunolol; the parasympathomimetic agent is pilocarpine; the sympathomimetic agent is epinephrine, brimonidine, iopidine, clonidine, or para-aminoclonidine, the carbonic anhydrase inhibitor is dorzolamide, acetazolamide, metazolamide or brinzolamide; the prostaglandin is latanoprost, travaprost, unoprostone, rescula, or S1033, the hypotensive lipid is lumigan, the neuroprotectant is eliprotil, R-eliprotil or memantine; and the 5-HT2 receptor agonist is 1-(2-aminopropyl)-3-methyl-1H-imidazol-6-ol fumarate or 2-(3-chloro-6-methoxy-indazol-1-yl)-1-methyl-ethylamine.